News

"Quantity" Half Achieves Double Prosperity: CGeneTech's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

  • Categories:Company News
  • Author:盛世小科
  • Origin:
  • Time of issue:2022-10-17
  • Views:0

(Summary description)Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.

"Quantity" Half Achieves Double Prosperity: CGeneTech's Class 1 New Hypoglycemic Drug Shenggliptin Uncovers Blindness Data

(Summary description)Today, Shengshi Tyco has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor shenggliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.

  • Categories:Company News
  • Author:盛世小科
  • Origin:
  • Time of issue:2022-10-17
  • Views:0

"Quantity" Half Achieves Double Prosperity: CGeneTech's Class 1 New Hypoglycemic Drug Cetagliptin Uncovers Blindness Data

Today, CGeneTech has completed a key clinical study on a class 1 new hypoglycemic drug under development: phase III clinical trial of DPP-4 inhibitor Cetagliptin in the treatment of type 2 diabetes. A dose of 50mg can reach the preset end point of the trial. A therapeutic dose of "half the dose" will further improve the safety of this drug and is expected to become the best hypoglycemic drug in the same class.

The full name of DPP-4 is dipeptidyl peptidase-4. DPP-4 inhibitors are becoming increasingly popular in China. In 2021, the market size of such drugs (all imported) will be nearly 7 billion yuan, and the future is promising. Public data show that such drugs can not only inhibit DPP-4, prevent it from inactivating glucagon like peptide-1 (GLP-1) and glucose dependent insulin secreting polypeptide (GIP), but also promote insulin release and inhibit islets α The cells secrete glucagon, increase insulin level, reduce blood sugar, and are not easy to induce hypoglycemia and weight gain. The mechanism of action of such drugs is consistent with the mechanism of human physiological regulation of blood sugar, which is called "the most intelligent hypoglycemic drug" by experts.

Cetagliptin is a Class 1 innovative drug independently developed by CGeneTech. As a new type of oral DPP-4 inhibitor, it has the advantages of high selectivity and strong inhibition. It has been selected for the National Twelfth Five Year Plan and the 13th Five Year Plan "Major New Drug Creation" project, and exempted from Phase II clinical trials and directly entered Phase III trials. CGeneTech has carried out two key phase III clinical trials of "Cetagliptin in the treatment of type 2 diabetes" in China. Professor Ji Linong, director of Endocrinology Department of Peking University People's Hospital, director of diabetes center of Peking University, and former president of Western Pacific region of International Diabetes alliance, is the leading pi. The research contents are the phase III trial of Cetagliptin tablets alone and the phase III trial of Cetagliptin tablets combined with metformin, About 1000 subjects with type 2 diabetes were enrolled.

The unblinding results of the phase III clinical trial of Cetagliptin showed that the decrease of HbA1c in the 50mg dose group (low-dose group) of Cetagliptin tablets reached the main clinical end point at the end of the 24th week, which was significantly better than that in the control group. After 28 weeks, the 100mg dose group (high-dose group) of Cetagliptin also showed good drug safety, and the incidence of adverse reactions was similar to that of the placebo group. Subsequently, the company will submit the listing application of Cetagliptin to the State Drug Administration as soon as possible in accordance with the relevant provisions of the national drug registration, so as to benefit the majority of diabetes patients in China as soon as possible.

CGeneTech was founded in Suzhou Industrial Park in 2010. Its core team has decades of experience in the whole life cycle of international drugs and is committed to the research, development and industrialization of small molecule innovative drugs for breakthrough therapies. Relying on the integrated drug R&D technology platform and diversified business vision, the company has built a rich pipeline of innovative drugs, covering many disease fields such as hypoglycemic, anti-cancer and rare diseases. In addition to Cetagliptin, three anti-cancer drugs developed by the company have entered the clinic, two of which have been approved by the FDA of the United States, making a solid step forward for the company's innovative drugs to go abroad.

Shengshi

Shengshi Taike has been awarded the "Double Yellow Egg" of Jiangsu Province's innovation and entrepreneurship talents

Jiangxiang is near Xiaoman, with warm air and moving grasshoppers. Recently, the selection results of Jiangsu Province's "Double Innovation Plan" for 2024 have been officially announced. Shengshi Taike's talent team has won the "Double Yellow Egg" award: the core team led by Dr. Wang Tong, Chief Scientific Officer, has been successfully selected as the "Double Innovation Team" in Jiangsu Province in 2024, and is the only "Innovation Team" in the field of biomedicine in Suzhou; Dr. Zhao Jiahong, Chief Medical Officer, has been successfully selected as a "Double Innovation Talent" in Jiangsu Province in 2024. The "Double Innovation Plan" in Jiangsu Province mainly focuses on introducing and funding scarce talents in the "high-precision and cutting-edge" and "bottleneck" fields, supporting the development of new technologies in key areas, and is an important brand project for talent work in Jiangsu Province. This plan focuses on the key industries prioritized for development in Jiangsu Province, playing an important role in enhancing independent innovation capabilities, promoting industrial structure optimization and upgrading, and driving rapid economic development. Dr. Wang Tong was just awarded the title of "Double Innovation Talent" in Jiangsu Province last year, and this time he led the company's core team to win the honor of "Double Innovation Team" in Jiangsu Province, fully reflecting the continuous innovation ability of the company's talent team. Dr. Wang Tong, as the Chief Scientific Officer of Shengshi Taike, has over 20 years of experience in the full chain drug research and management of top pharmaceutical companies and research institutes in the United States. He is a strategic scientist who can break through key technologies, drive emerging disciplines, and promote the new drug industry. Since joining Shengshi Taike, I have been awarded the title of leading technology talent at all levels, bringing innovative thinking and advanced technological means to the company. I have integrated and formed a complete new drug development and industrialization platform, leading the company's R&D team to accelerate the development of the new drug product pipeline. One of the core product pipelines, the hypoglycemic drug sengliptin, has been launched for sale. Dr. Zhao Jiahong, a core member of the "Double Creation Team", was also awarded the honor of "Double Creation Talent" in Jiangsu Province this time. Dr. Zhao Jiahong, as the Chief Medical Officer of Shengshi Taike, has over 20 years of experience in drug clinical trials and team management, and is an external expert of CDE; Has rich practical experience in medical affairs and early drug development, clinical development strategies, and international multicenter clinical trials, and has led and participated in over 600 clinical projects; I also have some experience in post market re evaluation of drugs. Since joining Shengshi Taike, I have been fully responsible for the company's new drug clinical development strategy and pathway, as well as post market expansion research and other important tasks. Among the core members of the "Double Creation Team", Dr. Lu Qin graduated from Fudan University with a major in Medical Systems Biology and holds the associate senior professional title. She has achieved fruitful research results in the field of biology, published multiple high-quality papers, obtained nearly 10 authorized invention patents, led the company's biology team to complete multiple project research tasks, and won multiple honors such as leading the park. Dr. Ouyang Zhenwu graduated from the Organic Chemistry Department of the Chinese Academy of Sciences. He has demonstrated outstanding academic and professional achievements in the field of pharmaceutical chemistry. He has published six high-quality papers in internationally renowned chemical journals, demonstrating his profound skills in chemical synthesis and drug design. Since joining the company, Dr. Ouyang has repeatedly used "innovative synthesis methods" to simplify the synthesis route, which not only significantly improves the efficiency of new drug screening, but also saves costs for the company in new drug development. Shengshi Taike, composed of these innovative talent teams, is a biotechnology company in the commercial stage. The core team has decades of experience in the entire lifecycle of international drugs and is committed to the research and industrialization of high-quality and differentiated small molecule innovative drugs. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives.
2025-05-22
Media

Media Attention | Yu Qiang, an "unsmart" entrepreneur, and his new diabetes drug Sengliptin

Qiang Yu, the founder and CEO of CGeneTech, a doctor of chemistry from Peking University, founded a biotechnology company in the United States at the beginning of this century, and later returned to China to found CGeneTech and developed a new type 2 diabetes drug, a new generation of DPP-4 inhibitor senpaglitin, which has now been approved for marketing.
2025-04-16

Contact Us

Add:Room 101, Bld C11, 218 Xinghu Rd,Suzhou industrial Park,China, 215123

Tel: +86-512-62956960(Recruitment)

         +86-512-62956961(marketing)

Copyright © 2022  CGeneTech (Suzhou, China) Co., Ltd.  All rights reserved.  苏ICP备2022006552号-1  Powered by 300.cn  SEO